Protein C, Human, mAb PC107
Monoclonal antibody PC107 is specific for activated Protein C (APC). Protein C (PC) is an important regulator of the blood coagulation system. The anticoagulant PC is converted to activated protein C (APC) by the thrombomodulin (TM)-thrombin complex on the phospholipid surface of endothelial cells, monocytes, and platelets. This process is enhanced in the presence of the endothelial protein C receptor (EPCR). In addition to its regulatory function in the blood coagulation system, studies indicate important roles for APC in inflammatory processes. The administration of APC prevents lethal effects of Escherichia coli-associated sepsis in experimental animal models and appears effective for the treatment of patients with meningococcemia or acquired PC deficiency. Treatment with APC improves the clinical outcome of patients with sepsis. The anti-inflammatory activity of APC depends on its ability to suppress the secretion of cytokines as tumor necrosis factor-alpha by inflammatory cells, the activation and extravasation of leukocytes and the expression and function of adhesion molecules. APC may also suppress the expression of growth factors and members of nuclear factor-kB (NF-kB) family of transcription factors. The monoclonal antibody PC107 is specific for activated human protein C (APC) and it lacks reactivity for Protein C. The monoclonal antibody recognizes the light chain of the APC molecule.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA